ABN Amro Investment Solutions Acquires New Holdings in IDEXX Laboratories, Inc. $IDXX

ABN Amro Investment Solutions bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,283 shares of the company’s stock, valued at approximately $1,761,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of IDEXX Laboratories by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after purchasing an additional 146,427 shares during the last quarter. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 2.3% in the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after purchasing an additional 54,402 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after buying an additional 825,965 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after buying an additional 884,808 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 0.5% in the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock valued at $489,832,000 after buying an additional 5,418 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 1.6%

IDEXX Laboratories stock opened at $689.93 on Friday. The stock has a 50-day moving average price of $651.74 and a 200 day moving average price of $587.72. The company has a market capitalization of $55.09 billion, a price-to-earnings ratio of 57.45, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm posted $2.80 EPS. IDEXX Laboratories’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Piper Sandler reissued a “neutral” rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. BTIG Research upped their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.